TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment options for peripheral T-cell lymphoma
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Optimal therapy for peripheral T-cell lymphoma is unclear for both pediatric and adult patients.
Treatment options for peripheral T-cell lymphoma include the following:
Chemotherapy.
Radiation therapy.
Allogeneic or autologous HSCT.[47]
Source links and citations
There have been four retrospective analyses of treatment and outcome for pediatric patients with peripheral T-cell lymphoma.
Evidence (treatment of peripheral T-cell lymphoma):
The United Kingdom Children's Cancer Study Group (UKCCSG) examined 25 children diagnosed with peripheral T-cell lymphoma over a 20-year period and reported the following:[37]
Source links and citations
The United Kingdom Children's Cancer Study Group (UKCCSG) examined 25 children diagnosed with peripheral T-cell lymphoma over a 20-year period and reported the following:[37]
A 5-year survival rate of approximately 50%.
The United Kingdom Children's Cancer Study Group (UKCCSG) examined 25 children diagnosed with peripheral T-cell lymphoma over a 20-year period and reported the following:[37]
The UKCCSG also observed that the use of acute lymphoblastic leukemia–like therapy, instead of NHL therapy, produced a superior outcome.
The COG reported on 20 patients older than 8 years who were treated on Pediatric Oncology Group NHL trials.[38]
Source links and citations
The COG reported on 20 patients older than 8 years who were treated on Pediatric Oncology Group NHL trials.[38]
Eight of ten patients with low-stage disease achieved long-term disease-free survival, compared with only four of ten patients with high-stage disease.
In a study of Japanese children with peripheral T-cell lymphoma (N = 21), treatment included chemotherapy (n = 18), radiation therapy (n = 2), and autologous (n = 2) and allogeneic (n = 9) HSCT.[48]
Source links and citations
In a study of Japanese children with peripheral T-cell lymphoma (N = 21), treatment included chemotherapy (n = 18), radiation therapy (n = 2), and autologous (n = 2) and allogeneic (n = 9) HSCT.[48]
The 5-year OS rate was 85.2%.
The Berlin-Frankfurt-Münster study group reported 38 cases of peripheral T-cell lymphoma acquired over a 26-year period.[40][Level of evidence C2]
Source links and citations
The Berlin-Frankfurt-Münster study group reported 38 cases of peripheral T-cell lymphoma acquired over a 26-year period.[40][Level of evidence C2]
Patients with peripheral T-cell lymphoma, NOS (n = 18), most with advanced disease (stage III [n = 10] and stage IV [n = 5]), were usually treated with anaplastic large cell lymphoma protocols and had a 10-year EFS rate of 61%.
The Berlin-Frankfurt-Münster study group reported 38 cases of peripheral T-cell lymphoma acquired over a 26-year period.[40][Level of evidence C2]
Patients with NK/T-cell lymphoma (n = 9) fared poorly, with a 10-year EFS rate of 17%.
The Berlin-Frankfurt-Münster study group reported 38 cases of peripheral T-cell lymphoma acquired over a 26-year period.[40][Level of evidence C2]
This series also included five patients with hepatosplenic T-cell lymphoma and five patients with subcutaneous panniculitis-like T-cell lymphoma.
For more information about the treatment of adults, see Peripheral T-Cell Non-Hodgkin Lymphoma Treatment.
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice